Industry

– STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high … [Read more…]

LEWISVILLE, Texas–(BUSINESS WIRE)–CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry, has been selected to exhibit the CareView Patient Safety System®, including its patented, predictive Virtual Bed Rails® and Virtual Chair Rails® technology, at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest member-driven health care … [Read more…]

Respected leaders bring deep industry expertise and diverse perspectives to further enable company’s substantial growth CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the appointment of Henrietta Fore and Stacy Enxing Seng to the company’s Board of Directors, effective immediately. “The addition of Henrietta and Stacy to Imperative Care’s Board of Directors will prove invaluable as … [Read more…]

Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell disease FORT COLLINS, Colo.–(BUSINESS WIRE)–Cetya Therapeutics, Inc. today announced the addition of Dr. Anthony Wutoh, Provost and Chief Academic Officer of Howard University, to its Board of Directors. Dr. Wutoh received a B.A. in Biochemistry … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–$DFCO #BrianBonar–An innovator in clean energy, healthcare, and technology, Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada Financial Corporation,” “Dalrada”) announced the expansion of its executive leadership team naming Brian McGoff as President and Chief Operating Officer. Mr. McGoff’s achievements include implementing cost-effective strategies for executing domestic and international growth, building strong teams, and delivering … [Read more…]

Borrowing capacity increases by $175 million Base interest rate fixed on $150 million HOUSTON–(BUSINESS WIRE)–U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced the closing of a $325 million, five-year credit facility that includes a $150 million … [Read more…]

– Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease – – Presentation at the 12th International Symposium on Pneumococci and Pneumococcal Diseases – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of … [Read more…]

GC 2400 solution streamlines performance and delivers superior precision for high throughput environments WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the GC 2400™ Platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab … [Read more…]

Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]

New Drug Application filing anticipated based on positive data from interim analysis WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a statistically … [Read more…]